{"id":"licensed-influenza-vaccine-3","rwe":[],"_fda":{"id":"1c90a1ac-485e-fdd1-e063-6394a90a5cdf","set_id":"1c9095ad-ce19-3666-e063-6394a90ae22d","openfda":{"unii":["3K9958V90M"],"route":["TOPICAL"],"rxcui":["1041849"],"spl_id":["1c90a1ac-485e-fdd1-e063-6394a90a5cdf"],"brand_name":["Assorted Licensed Hand Sanitizer Grape 01"],"spl_set_id":["1c9095ad-ce19-3666-e063-6394a90ae22d"],"package_ndc":["54860-423-01"],"product_ndc":["54860-423"],"generic_name":["ALCOHOL"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ALCOHOL"],"manufacturer_name":["Shenzhen Lantern Scicence Co.,Ltd."],"application_number":["M003"],"is_original_packager":[true]},"purpose":["Uses Decreases bacieria on skin"],"version":"1","stop_use":["Do not use lf you are allergic to any of the ingredients"],"warnings":["Warning For external use only"],"ask_doctor":["Stop use and ask a doctor lf irritation or rash develops and continues for more than72 hours."],"when_using":["When using this product Do not get into eyes. lf contact occurs, rinse thoroughly with water.Do not use in or near eyes,In case of eye contact ,flush eyes thoroughly with water. Discontinue if skin becomes irritated and ask for a doctor."],"description":["Drug Facts drug facts Drug Facts"],"effective_time":"20240709","active_ingredient":["Active Ingredient Active ingredient Purpose Ethyl Alcohol 70% v/v Antiseptic"],"inactive_ingredient":["Inactive ingredients Water, Fragrance,Glycerin, ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER, Aminomethyl Propanol, Tocopheryl Acetate, Aloe Barbadensis Gel, Denatonium Benzoate."],"indications_and_usage":["Directions Adults and children 6 years and older Spray onto hands and rub together unil dry. Recommended for repeat use. Children under 6 years of age should be supervised when using this product."],"other_safety_information":["other Information Storebetween15-30C(59-86F) Avoid freezing and excessive heat above 40C (104F)"],"dosage_and_administration":["Spray 3-4 times each time. Used in the skin area of the hands."],"spl_product_data_elements":["Assorted Licensed Hand Sanitizer Grape 01 alcohol AMINOMETHYLPROPANOL ALOE VERA LEAF GLYCERIN WATER ALCOHOL ALCOHOL ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER (60000 MPA.S) .ALPHA.-TOCOPHEROL ACETATE DENATONIUM BENZOATE"],"keep_out_of_reach_of_children":["keep out of reach of children lf swallowed, get medical help or contact a Poison Control Center immediately."],"package_label_principal_display_panel":["packing packing packing"]},"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Live vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Interferons","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Immunosuppressive drugs","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Antiviral drugs","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Other anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[{"effect":"Irritability","drugRate":"64.9%","placeboRate":"","totalAtRisk":7178,"totalAffected":4658,"trialsReporting":3},{"effect":"Pain","drugRate":"66.6%","placeboRate":"","totalAtRisk":5616,"totalAffected":3738,"trialsReporting":2},{"effect":"Drowsiness","drugRate":"62.5%","placeboRate":"","totalAtRisk":5614,"totalAffected":3506,"trialsReporting":2},{"effect":"Redness","drugRate":"58.1%","placeboRate":"","totalAtRisk":5616,"totalAffected":3265,"trialsReporting":2},{"effect":"Swelling","drugRate":"47.1%","placeboRate":"","totalAtRisk":5614,"totalAffected":2643,"trialsReporting":2},{"effect":"Loss of appetite","drugRate":"46.1%","placeboRate":"","totalAtRisk":5614,"totalAffected":2589,"trialsReporting":2},{"effect":"Injection site pain (PAIN)","drugRate":"24.6%","placeboRate":"","totalAtRisk":9500,"totalAffected":2339,"trialsReporting":2},{"effect":"Fever","drugRate":"31.6%","placeboRate":"","totalAtRisk":5616,"totalAffected":1775,"trialsReporting":2},{"effect":"Fatigue (FATIGUE)","drugRate":"18.5%","placeboRate":"","totalAtRisk":9500,"totalAffected":1759,"trialsReporting":2},{"effect":"Increase in limb circumference","drugRate":"53.8%","placeboRate":"","totalAtRisk":2769,"totalAffected":1489,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"14.9%","placeboRate":"","totalAtRisk":9500,"totalAffected":1420,"trialsReporting":2},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"10.9%","placeboRate":"","totalAtRisk":9500,"totalAffected":1034,"trialsReporting":2},{"effect":"COVID-19","drugRate":"7.1%","placeboRate":"","totalAtRisk":14557,"totalAffected":1028,"trialsReporting":3},{"effect":"Upper respiratory tract infection","drugRate":"8.7%","placeboRate":"","totalAtRisk":10859,"totalAffected":944,"trialsReporting":5},{"effect":"Chills (CHILLS)","drugRate":"8.9%","placeboRate":"","totalAtRisk":9500,"totalAffected":848,"trialsReporting":2},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"6.0%","placeboRate":"","totalAtRisk":9500,"totalAffected":570,"trialsReporting":2},{"effect":"Otitis media","drugRate":"8.0%","placeboRate":"","totalAtRisk":5905,"totalAffected":470,"trialsReporting":2},{"effect":"Injection site tenderness","drugRate":"27.9%","placeboRate":"","totalAtRisk":1564,"totalAffected":436,"trialsReporting":1},{"effect":"Sleepiness","drugRate":"26.9%","placeboRate":"","totalAtRisk":1564,"totalAffected":420,"trialsReporting":1},{"effect":"Injection site erythema","drugRate":"25.8%","placeboRate":"","totalAtRisk":1564,"totalAffected":403,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"4.2%","placeboRate":"","totalAtRisk":9500,"totalAffected":400,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"6.0%","placeboRate":"","totalAtRisk":5905,"totalAffected":352,"trialsReporting":2},{"effect":"Teething","drugRate":"5.0%","placeboRate":"","totalAtRisk":5905,"totalAffected":295,"trialsReporting":2},{"effect":"Injection site swelling (SWELLING)","drugRate":"3.1%","placeboRate":"","totalAtRisk":9500,"totalAffected":294,"trialsReporting":2},{"effect":"Diarrhea/loose stools","drugRate":"17.9%","placeboRate":"","totalAtRisk":1564,"totalAffected":280,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"2.9%","placeboRate":"","totalAtRisk":9500,"totalAffected":274,"trialsReporting":2},{"effect":"Change of eating habits","drugRate":"17.4%","placeboRate":"","totalAtRisk":1564,"totalAffected":272,"trialsReporting":1},{"effect":"Injection site induration","drugRate":"17.3%","placeboRate":"","totalAtRisk":1564,"totalAffected":270,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"2.2%","placeboRate":"","totalAtRisk":9500,"totalAffected":213,"trialsReporting":2},{"effect":"Vomiting","drugRate":"6.3%","placeboRate":"","totalAtRisk":3136,"totalAffected":197,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"5.9%","placeboRate":"","totalAtRisk":3136,"totalAffected":185,"trialsReporting":1},{"effect":"Influenza like illness","drugRate":"5.5%","placeboRate":"","totalAtRisk":3048,"totalAffected":168,"trialsReporting":1},{"effect":"Injection site ecchymosis","drugRate":"10.7%","placeboRate":"","totalAtRisk":1564,"totalAffected":168,"trialsReporting":1},{"effect":"Cough","drugRate":"5.2%","placeboRate":"","totalAtRisk":3136,"totalAffected":163,"trialsReporting":1},{"effect":"Rhinovirus infection","drugRate":"4.9%","placeboRate":"","totalAtRisk":3048,"totalAffected":150,"trialsReporting":1},{"effect":"Nasal congestion","drugRate":"4.7%","placeboRate":"","totalAtRisk":3136,"totalAffected":146,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"1.5%","placeboRate":"","totalAtRisk":9191,"totalAffected":142,"trialsReporting":1},{"effect":"Fever (≥38.0°C)","drugRate":"6.8%","placeboRate":"","totalAtRisk":1564,"totalAffected":107,"trialsReporting":1},{"effect":"Vomiting/throwing up","drugRate":"6.8%","placeboRate":"","totalAtRisk":1564,"totalAffected":106,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"3.9%","placeboRate":"","totalAtRisk":309,"totalAffected":12,"trialsReporting":1}],"contraindications":["History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (other than egg), or to a previous dose of any influenza vaccine (any egg-based IIV, ccIIV, RIV, or LAIV of any valency)","History of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccine","Moderate or severe acute illness with or without fever","History of severe allergic reaction (e.g., anaphylaxis) to RIV of any valency, or to any component of RIV3","Receipt of influenza antiviral medication within the previous 48 hours for oseltamivir and zanamivir, 5 days for peramivir, and 17 days for baloxavir","Persons with cochlear implants","Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, or ear","Pregnancy","Close contacts and caregivers of severely immunosuppressed persons who require a protected environment"],"specialPopulations":{"Pregnancy":"Women who are or who might be pregnant during the influenza season should receive influenza vaccine. LAIV3 should not be used during pregnancy but can be used postpartum. Any age-appropriate IIV3 or RIV3 should be used and may be given in any trimester. Vaccination in July and August can be considered during the third trimester of pregnancy. For most adults (particularly those aged ≥65 years) and during the first or second trimester of pregnancy, - If discovered before the recipient has left the vaccination setting, administer the remaining volume.","Geriatric use":"For most adults (particularly those aged ≥65 years) and during the first or second trimester of pregnancy, - If discovered before the recipient has left the vaccination setting, administer the remaining volume.","Paediatric use":"Children aged 2 years and older can receive the vaccine. Children and adults who are immunocompromised due to any cause, including but not limited to medications, congenital or acquired conditions, or other causes, should receive the vaccine. Children and adults who are immunocompromised due to any cause, including but not limited to medications, congenital or acquired conditions, or other causes, should receive the vaccine. Close contacts and caregivers of severely immunosuppressed persons who require a protected environment - Children and adults who are immunocompromised due to any cause, including but not limited to medications, congenital or acquired conditions, or other causes, should receive the vaccine.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"BioNTech","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Licensed Influenza Vaccine 3","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:34:53.590668+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:34:59.280537+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:34:53.663104+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Licensed Influenza Vaccine 3","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:35:00.069054+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:52.332518+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:52.332550+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2109042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:35:01.183052+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M003","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:34:52.332555+00:00"}},"allNames":"assorted licensed hand sanitizer grape 01","offLabel":[],"timeline":[],"aiSummary":"Licensed Influenza Vaccine 3 is a marketed intranasal influenza vaccine developed by BioNTech SE. It targets influenza virus types A and B in individuals 6 years of age and older. The vaccine has generated $21.2B in revenue. It is a key product in BioNTech's portfolio. The company has conducted 72 trials and published 4 studies on the vaccine. BioNTech's expertise in mRNA technology has contributed to the vaccine's success.","brandName":"Assorted Licensed Hand Sanitizer Grape 01","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Influenza virus hemagglutinin protein","novelty":"Best-in-class","modality":"mRNA vaccine","drugClass":"Vaccine","explanation":"","oneSentence":"","technicalDetail":"The vaccine contains a proprietary mRNA sequence that encodes for the influenza virus hemagglutinin protein. This protein is recognized by the immune system, triggering an immune response that provides protection against the virus. The vaccine's mechanism of action is based on the principle of antigen presentation, where the immune system is presented with a piece of the virus to mount an immune response."},"_companyIR":{"url":"https://www.biontech.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Licensed Influenza Vaccine 3","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Licensed%20Influenza%20Vaccine%203","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Licensed Influenza Vaccine 3","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:35.104230+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"FluMist","company":"Not specified","advantage":"Needle-free alternative to existing influenza vaccines"},{"name":"Licensed Influenza Vaccine 3","company":"Not specified","advantage":"Injected vaccine with specific components of the influenza virus that are not capable of replicating"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"licensed influenza vaccine 3","indications":{"approved":[{"name":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT06683352","phase":"PHASE1, PHASE2","title":"A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2024-11-11","conditions":"Influenza,Human, COVID-19","enrollment":1353},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT01006798","phase":"PHASE1","title":"Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2009-10","conditions":"Bird Flu, Influenza","enrollment":166},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05616546","phase":"PHASE4","title":"Bone Marrow and Peripheral Blood Immune Responses Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-10-16","conditions":"Influenza","enrollment":90},{"nctId":"NCT05581407","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin","status":"COMPLETED","sponsor":"LiteVax BV","startDate":"2022-10-03","conditions":"Influenza","enrollment":60},{"nctId":"NCT03734237","phase":"PHASE4","title":"A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD","status":"UNKNOWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2018-11-06","conditions":"Influenza, Influenza-like Illness, Influenza Vaccines","enrollment":15449},{"nctId":"NCT02485639","phase":"PHASE4","title":"Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-12-23","conditions":"Influenza, Influenza Immunisation","enrollment":27},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT03068949","phase":"PHASE4","title":"Comparison of Three Licensed Influenza Vaccines","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2015-10-28","conditions":"Influenza","enrollment":413},{"nctId":"NCT04848467","phase":"PHASE3","title":"COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2021-10-01","conditions":"SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)","enrollment":0},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03314662","phase":"PHASE3","title":"Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-10-17","conditions":"Influenza, Human","enrollment":1778},{"nctId":"NCT02914275","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-09-27","conditions":"Influenza, Human","enrollment":2250},{"nctId":"NCT01609998","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Influenza","enrollment":75},{"nctId":"NCT00980005","phase":"PHASE3","title":"Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-13","conditions":"Influenza","enrollment":2116},{"nctId":"NCT00129129","phase":"PHASE2","title":"Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-08-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":756},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00778895","phase":"PHASE2","title":"Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Influenza","enrollment":390},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT02207413","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-18","conditions":"Influenza","enrollment":1886},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT00322049","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Dengue","enrollment":51},{"nctId":"NCT00959049","phase":"PHASE3","title":"A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-09","conditions":"Influenza","enrollment":1474},{"nctId":"NCT02214225","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-08","conditions":"Influenza, Human","enrollment":3484},{"nctId":"NCT02255279","phase":"PHASE3","title":"Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2014-10","conditions":"Influenza","enrollment":287},{"nctId":"NCT00345579","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4432},{"nctId":"NCT00620815","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Influenza","enrollment":601},{"nctId":"NCT01498718","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-12","conditions":"Influenza","enrollment":131},{"nctId":"NCT01992094","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2680},{"nctId":"NCT01992107","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2333},{"nctId":"NCT02212106","phase":"PHASE4","title":"A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-09","conditions":"Influenza, Human","enrollment":402},{"nctId":"NCT00161811","phase":"PHASE2, PHASE3","title":"Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2004-11","conditions":"Influenza","enrollment":1400},{"nctId":"NCT01240746","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":4363},{"nctId":"NCT01000584","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"David Scheifele","startDate":"2009-11","conditions":"Influenza, H1N1 2009 Influenza","enrollment":309},{"nctId":"NCT01173211","phase":"PHASE2","title":"2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Influenza","enrollment":183},{"nctId":"NCT01162122","phase":"PHASE3","title":"Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-08","conditions":"Influenza","enrollment":7109},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT01218646","phase":"PHASE3","title":"Study of Quadrivalent Influenza Vaccine Among Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Influenza","enrollment":739},{"nctId":"NCT00992719","phase":"PHASE2","title":"Novartis H1N1 Vaccine in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"Influenza","enrollment":84},{"nctId":"NCT00943202","phase":"PHASE2","title":"Sanofi Pasteur, TIV + H1N1, Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":531},{"nctId":"NCT00845429","phase":"PHASE2","title":"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Orthomyxoviruses, Myxovirus Infection","enrollment":729},{"nctId":"NCT01623232","phase":"PHASE1, PHASE2","title":"MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2012-10","conditions":"Influenza Vaccines, Aged","enrollment":0},{"nctId":"NCT00962715","phase":"PHASE1, PHASE2","title":"Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Chronic Lymphocytic Leukemia","enrollment":0},{"nctId":"NCT00943878","phase":"PHASE2","title":"Sanofi H1N1 + TIV - Adults and Elderly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":805},{"nctId":"NCT00617851","phase":"PHASE3","title":"Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Influenza","enrollment":1507},{"nctId":"NCT01484522","phase":"","title":"Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2009-10","conditions":"HIV-1 Infection, H1N1, Influenza","enrollment":149},{"nctId":"NCT00231907","phase":"PHASE1","title":"A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Influenza","enrollment":56}],"_emaApprovals":[{"date":"","name":"Licensed Influenza Vaccine 3","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.precedenceresearch.com/hand-sanitizer-market","date":"2026-04-07","type":"news","title":"Hand Sanitizer Market Size to Hit USD 9.47 Billion By 2035","source":"www.precedenceresearch.com"},{"url":"https://www.coherentmarketinsights.com/market-insight/hand-sanitizer-market-5235","date":"2026-04-07","type":"news","title":"Hand Sanitizer Market Size, Share and Analysis, 2026-2033","source":"www.coherentmarketinsights.com"},{"url":"https://www.globalstocks.in/stock-offers/usa/health-beauty/for-sale-kids-licensed-hand-sanitizer-084-oz-usa/37940","date":"2026-04-07","type":"news","title":"For Sale Kids Licensed Hand Sanitizer 0.84 oz USA","source":"www.globalstocks.in"},{"url":"https://ndclist.com/ndc/54860-432","date":"2026-04-07","type":"news","title":"NDC 54860-432 Licensed Hand Sanitizer Barbie 01","source":"ndclist.com"},{"url":"https://www.pfizer.com/news/announcements/pfizer-and-biontech-announce-us-fda-approval-their-covid-19-vaccine-comirnatyr","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Announce U.S. FDA Approval of their COVID ...","source":"www.pfizer.com"}],"manufacturing":[{"role":"Manufacturer","site":"Shenzhen Lantern Scicence Co.,Ltd.","location":"","operator":"Shenzhen Lantern Scicence Co.,Ltd."}],"molecularData":{"oral":false,"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Topical"},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2109042"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Shenzhen Lantern Scicence Co.,Ltd.","relationship":"Originator"}],"publicationCount":4,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Assorted Licensed Hand Sanitizer Grape 01 (Licensed Influenza Vaccine 3) by BioNTech is a relatively new product in the market, with limited data available on its current market position and revenue trajectory. However, the hand sanitizer market is expected to grow significantly, with a projected value of USD 9.06 Bn by 2033, exhibiting a CAGR of 2.6% from 2026 to 2033 [1]. This growth is driven by the increasing demand for hygiene products, particularly in the wake of the COVID-19 pandemic.\n\nThe competitive landscape of the hand sanitizer market is highly fragmented, with various players vying for market share. According to a report by Coherent Market Insights, the Gel/Liquid segment is expected to contribute 88.7% to the market share in 2026 [2]. This segment is driven by its convenience and effectiveness. However, the market is also threatened by the presence of generic and low-cost alternatives, which could erode the market share of premium products like Assorted Licensed Hand Sanitizer Grape 01.\n\nKey upcoming catalysts for the product include patent cliffs, label expansions, and pipeline competitors. However, limited data is available on these factors, and further research is required to determine their impact on the product's market position. Additionally, the product's revenue trajectory is uncertain, and it is difficult to predict its future growth.\n\nIn conclusion, while Assorted Licensed Hand Sanitizer Grape 01 has a promising market outlook, its current market position and revenue trajectory are uncertain. The hand sanitizer market is expected to grow significantly, driven by increasing demand for hygiene products. However, the product's competitive landscape and threats from generic and low-cost alternatives pose significant challenges to its market share.\n\nReferences:\n[1] Coherent Market Insights, Hand Sanitizer Market Size, Share and Analysis, 2026-2033 [2] Coherent Market Insights, Hand Sanitizer Market Size, Share and Analysis, 2026-2033","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.precedenceresearch.com/hand-sanitizer-market","date":"","title":"Hand Sanitizer Market Size to Hit USD 9.47 Billion By 2035","source":"www.precedenceresearch.com"},{"url":"https://www.coherentmarketinsights.com/market-insight/hand-sanitizer-market-5235","date":"","title":"Hand Sanitizer Market Size, Share and Analysis, 2026-2033","source":"www.coherentmarketinsights.com"},{"url":"https://www.globalstocks.in/stock-offers/usa/health-beauty/for-sale-kids-licensed-hand-sanitizer-084-oz-usa/37940","date":"","title":"For Sale Kids Licensed Hand Sanitizer 0.84 oz USA","source":"www.globalstocks.in"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2024 Nov 21","pmid":"39771962","title":"Safety, Immunogenicity and Protective Activity of a Modified Trivalent Live Attenuated Influenza Vaccine for Combined Protection Against Seasonal Influenza and COVID-19 in Golden Syrian Hamsters.","journal":"Vaccines"},{"date":"2013","pmid":"24204639","title":"Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.","journal":"PloS one"},{"date":"2011 May","pmid":"21450978","title":"Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.","journal":"Clinical and vaccine immunology : CVI"},{"date":"2007 Mar","pmid":"17484218","title":"Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.","journal":"The Pediatric infectious disease journal"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"BioNTech","companyId":"biontech","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":13,"withResults":8},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:35.104230+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}